Creo Medical Group (LON:CREO) Earns “House Stock” Rating from Shore Capital Group

Creo Medical Group (LON:CREO)‘s stock had its “house stock” rating reiterated by analysts at Shore Capital Group in a research note issued on Thursday,London Stock Exchange reports. They currently have a GBX 40 price objective on the stock. Shore Capital Group’s price target would suggest a potential upside of 185.71% from the company’s previous close.

Creo Medical Group Stock Performance

Shares of LON CREO opened at GBX 14 on Thursday. The firm has a market capitalization of £68.01 million, a price-to-earnings ratio of 14.00 and a beta of 1.62. Creo Medical Group has a one year low of GBX 9.52 and a one year high of GBX 18.50. The business has a fifty day simple moving average of GBX 13.67 and a 200 day simple moving average of GBX 13.27. The company has a current ratio of 3.22, a quick ratio of 2.19 and a debt-to-equity ratio of 8.20.

Creo Medical Group (LON:CREO) last posted its quarterly earnings results on Friday, May 22nd. The company reported GBX (0.04) earnings per share for the quarter. The business had revenue of GBX 600 million for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. Sell-side analysts expect that Creo Medical Group will post -10.0800005 EPS for the current year.

Insider Transactions at Creo Medical Group

In other Creo Medical Group news, insider Richard John Rees bought 6,250 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were acquired at an average cost of GBX 14 per share, for a total transaction of £875. Also, insider Craig Jonathan Gulliford bought 6,250 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were acquired at an average price of GBX 14 per share, for a total transaction of £875. 6.92% of the stock is currently owned by company insiders.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.